Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 9/20 | 0.57 |
| ▸ | HSP90B1 | P14625 | 7/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.32 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.32 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078262 | 0.81 | HSP90AA1 (0.57) | TRAP1HSP90B1HSP90AA1HSP90AB1 | |
| SCHEMBL1079346 | 0.77 | HSP90AA1 (0.60) | TRAP1HSP90B1HSP90AA1HSP90AB1 | |
| SCHEMBL28787805 | 0.76 | TRAP1 (0.36) | TRAP1HSP90B1HSP90AA1KCNH2GRIN2B | |
| SCHEMBL1057826 | 0.76 | TRAP1 (0.59) | TRAP1HSP90B1HSP90AA1KCNH2GRIN2B | |
| SCHEMBL1060933 | 0.76 | HSP90AA1 (0.56) | TRAP1HSP90B1HSP90AA1HSP90AB1 | |
| SCHEMBL12615628 | 0.74 | HSP90AA1 (0.59) | TRAP1HSP90B1HSP90AA1HSP90AB1 | |
| SCHEMBL1052264 | 0.73 | TRAP1 (0.73) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL1059998 | 0.71 | TRAP1 (0.54) | TRAP1HSP90B1HSP90AA1HSP90AB1 | |
| SCHEMBL1080760 | 0.71 | TRAP1 (0.56) | TRAP1HSP90B1HSP90AA1HSP90AB1 | |
| SCHEMBL3391833 | 0.71 | HSP90AA1 (0.57) | TRAP1HSP90B1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| EP-2273882-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | Poniard Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | TRAP1 443/4885HSP90B1 1036/4885HSP90AA1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.